These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 3180098)
1. Tissue-specific pharmacodynamics of 5-bromo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits. Stetson PL; Maybaum J; Wagner JG; Averill DR; Wollner IS; Knol JA; Johnson NJ; Yang ZM; Preiskorn D; Smith P Cancer Res; 1988 Dec; 48(23):6900-5. PubMed ID: 3180098 [TBL] [Abstract][Full Text] [Related]
2. Biochemical modulation of 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits. Stetson PL; Normolle DP; Knol JA; Johnson NJ; Yang ZM; Sakmar E; Prieskorn D; Terrio P; Knutsen CA; Ensminger WD J Natl Cancer Inst; 1991 Nov; 83(22):1659-67. PubMed ID: 1836238 [TBL] [Abstract][Full Text] [Related]
3. 5-Bromo-2'-deoxyuridine incorporation into DNA in hepatic VX2 tumor-bearing rabbits. Knol JA; Stetson PL; Wagner JG; Johnson NJ; Yang ZM; Prieskorn D; Terrio P; Knutsen CA; Ensminger WD J Surg Res; 1989 Aug; 47(2):112-6. PubMed ID: 2755115 [TBL] [Abstract][Full Text] [Related]
4. Kinetics of bromodeoxyuridine elimination from human colon cancer cells in vitro and in vivo. Lawrence TS; Davis MA; Stetson PL; Maybaum J; Ensminger WD Cancer Res; 1994 Jun; 54(11):2964-8. PubMed ID: 8187082 [TBL] [Abstract][Full Text] [Related]
5. Variability of 5-bromo-2'-deoxyuridine incorporation into DNA of human glioma cell lines and modulation with fluoropyrimidines. Mancini WR; Stetson PL; Lawrence TS; Wagner JG; Greenberg HS; Ensminger WD Cancer Res; 1991 Feb; 51(3):870-4. PubMed ID: 1824826 [TBL] [Abstract][Full Text] [Related]
6. Incorporation of 5-bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion. Knol JA; Walker SC; Robertson JM; Yang Z; DeRemer S; Stetson PL; Ensminger WD; Lawrence TS Cancer Res; 1995 Sep; 55(17):3687-91. PubMed ID: 7641176 [TBL] [Abstract][Full Text] [Related]
7. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer. Lawrence TS; Davis MA; Maybaum J; Mukhopadhyay SK; Stetson PL; Normolle DP; McKeever PE; Ensminger WD Cancer Res; 1992 Jul; 52(13):3698-704. PubMed ID: 1617642 [TBL] [Abstract][Full Text] [Related]
8. Sensitization of 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin cytotoxicity by 5-bromo-2'-deoxyuridine in human glioma. Mancini WR; Glaze ER; Stetson PL; Greenberg HS J Pharmacol Exp Ther; 1999 Jun; 289(3):1404-9. PubMed ID: 10336533 [TBL] [Abstract][Full Text] [Related]
9. Effect of 5-fluoro-2'-deoxyuridine (FdUrd) on 5-bromo-2'-deoxyuridine (BrdUrd) incorporation into DNA measured with a monoclonal BrdUrd antibody and by the BrdUrd/Hoechst quenching effect. Ellwart J; Dörmer P Cytometry; 1985 Nov; 6(6):513-20. PubMed ID: 2415309 [TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine. Ensminger WD; Walker SC; Stetson PL; Wagner JG; Knol JA; Lawrence TS; Andrews JC Cancer Res; 1994 Apr; 54(8):2121-4. PubMed ID: 8174116 [TBL] [Abstract][Full Text] [Related]
11. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. Chabner BA; Young RC J Clin Invest; 1973 Aug; 52(8):1804-11. PubMed ID: 4719662 [TBL] [Abstract][Full Text] [Related]
12. Bromodeoxyuridine-mediated radiosensitization in human glioma: the effect of concentration, duration, and fluoropyrimidine modulation. McLaughlin PW; Lawrence TS; Seabury H; Nguyen N; Stetson PL; Greenberg HS; Mancini WR Int J Radiat Oncol Biol Phys; 1994 Oct; 30(3):601-7. PubMed ID: 7928491 [TBL] [Abstract][Full Text] [Related]
13. Detection of 5-bromo-2-deoxyuridine (BrdUrd) incorporation with monoclonal anti-BrdUrd antibody after deoxyribonuclease treatment. Takagi S; McFadden ML; Humphreys RE; Woda BA; Sairenji T Cytometry; 1993; 14(6):640-8. PubMed ID: 8404370 [TBL] [Abstract][Full Text] [Related]
14. Bromodeoxyuridine incorporation into DNA of human leukemia cells is not concentration dependent. Powell BL; Gregory BW; Kute TE; Morgan TM; Lyerly ES; Capizzi RL Cytometry; 1990; 11(3):438-41. PubMed ID: 2340778 [TBL] [Abstract][Full Text] [Related]
15. Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions. Kuan HY; Smith DE; Ensmiger WD; Knol JA; DeRemer SJ; Yang Z; Stetson PL Cancer Res; 1996 Oct; 56(20):4724-7. PubMed ID: 8840990 [TBL] [Abstract][Full Text] [Related]
16. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine. Doiron A; Yapp DT; Olivares M; Zhu JX; Lehnert S Cancer Res; 1999 Aug; 59(15):3677-81. PubMed ID: 10446981 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2'-deoxycytidine. Russell KJ; Rice GC; Brown JM Cancer Res; 1986 Jun; 46(6):2883-7. PubMed ID: 3698014 [TBL] [Abstract][Full Text] [Related]
18. Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine. Buchsbaum DJ; Khazaeli MB; Davis MA; Lawrence TS Cancer; 1994 Feb; 73(3 Suppl):999-1005. PubMed ID: 8306292 [TBL] [Abstract][Full Text] [Related]
19. Steady-state arterial and hepatic venous plasma concentrations of 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine in animals--drugs which are subject to both splanchnic and extra-splanchnic elimination. Wagner JG; Stetson PL; Knol JA; Andrews JC; Walker-Andrews S; Knutsen CA; Johnson N; Prieskorn D; Terrio P; Yang Z Sel Cancer Ther; 1989; 5(4):193-203. PubMed ID: 2623384 [TBL] [Abstract][Full Text] [Related]
20. Improved methods for the determination of 5-bromo-2-deoxyuridine labelling index in clones and colonies growing in plasma clots. Di Nucci GD; Tazzari PL; Bontadini A; Tassi C; Dinota A; Pileri S; Gobbi M Basic Appl Histochem; 1990; 34(1):71-7. PubMed ID: 2337406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]